Across the globe, tech industry capacity keeps expanding steadily.

Frontier technology and biomedicine spearhead China's vigorous growth like the North Star.

Stay focused and single-minded in pursuit of excellence. Align with visionary entrepreneurs

who shoulder era missions and pursue selflessness. Discover outstanding pioneering enterprises to benefit humanity and society.

Keen in insight, upright in conduct.

Embrace cutting-edge tech, seek light amid future obscurity. Join like-minded partners, march firmly toward the light.

Welcome toZBJL CAPITAL

Truth, Unity & Innovation, Invest Long-term in High-Tech

Zhongbo Juli (Beijing) Investment Management Co., Ltd. (ZBJL Capital) is a rapidly growing, breakthrough-oriented private equity firm specializing in equity investments within the frontier technology sector, targeting "unicorns" with the potential to reshape the course of human civilization. "Gathering strength for the profound, achieving greatness in the refined." ZBJL Capital strives to go beyond merely creating wealth, delivering returns to investors, and fostering deep synergy with government guidance funds and industrial capital. By using finance as a bridge, the firm is dedicated to driving technology toward the good and life toward prosperity—allowing capital to become a benevolent variable in the evolution of civilization.
More
Today
2025
2021
2020
Partn
ership

Investment and
ecosystem driving
long-termism.

Leap

Successive funds
expanding investment
footprint.

Found
ation

Parallel frameworks
for frontier tech.

  • Stream Computing

    https://www.streamcomputing.com/

    Stream Semiconductor Technology (Guangzhou) Co., Ltd. was founded in April 2019.From its inception, the Company has established three core layouts:the technical route of designing high-performance data center chips based on the RISC-V instruction set,the development strategy of gradual evolution from Domain-Specific Architecture (DSA) for dedicated computing to general-purpose computing (CPU),and the product roadmap of taking AI chips as the starting point, deploying inference chips first followed by training chips.

  • Hebabiz Biotech

    https://www.huibaoyuan.com.cn/

    Hebabiz Biotechnology Co., Ltd. (Beijing) was founded in July 2011 by returned scholars from Yale University and their research team. Guided by patient needs and clinical value, the Company is committed to developing personalized, precise and optimized therapeutic solutions for the treatment of tumors and liver diseases. It also adopts cutting-edge biotechnology to systematically advance the modernization and technical level of traditional Chinese medicine.

  • Cardinal Operations

    https://www.shanshu.ai/

    Cardinal Operations (Beijing) Co., Ltd. was co-founded in 2016 by four PhD graduates from Stanford University. It is a leading AI decision technology service provider in China. Powered by COPT, China’s first intelligent computing solver as its core engine, the Company has built an end-to-end intelligent decision computing business system featuring intelligent computing power + optimization engine + decision technology middle platform + business scenarios. It provides flexible, lightweight and efficient decision optimization computing services for clients, solves practical challenges in production, supply chain, logistics and other business scenarios, and empowers enterprises to achieve digital transformation and secondary business growth.

  • Inna Pharma

    http://www.zhongbocapital.com

    Inna Pharma (Wuhan) Co., Ltd. was founded in February 2019. Upholding its mission of “the commitment to curing hundreds of millions of patients”, the Company has developed a series of first-in-class small-molecule inhibitors targeting the most crucial targets of the innate immune system.Its products are applicable to a variety of major human inflammatory diseases. The innovative drugs are designed as First-in-class, with some indications achieving Me-only status, boasting enormous exclusive market potential and filling multiple gaps in medical treatment and commercial markets.

  • Robosen

    https://www.robosen.cn/

    Robosen Robotics (Shenzhen) Co., Ltd. was founded in 2008. As a technology-driven enterprise, it has long focused on the field of service robots. The founding team consists of robotics scientists and industry enthusiasts, mastering a wealth of core technologies including digital electric transmission, robot proximity operation, force feedback, as well as miniature and heavy-duty servo actuators.

  • Immunophage Biopharma

    http://www.immunophage.com.cn/

    Immunophage Biopharmaceutical (Nanjing) Co., Ltd. was founded in 2016. It is a biopharmaceutical company dedicated to developing first-in-class innovative drugs targeting globally leading targets for the treatment of malignant tumors, autoimmune diseases and neurodegenerative diseases.The Company is capable of target discovery and validation, with solid fundamental research strength and sustained innovation capacity as well as high growth potential. It has established advanced platforms for the screening and evaluation of small-molecule and macromolecular drugs, and built a strong management and R&D team together with a rich pipeline of new drug candidates.

  • Pera Global

    http://www.peraglobal.com/

    Pera Global Technology Co., Ltd. was founded in December 2003 and headquartered in Beijing. It is a national key software enterprise and a national-level key Specialized, Sophisticated, Unique and Innovative Little Giant Enterprise. As a leading enterprise in China’s CAE engineering simulation industry, it has been deeply engaged in this field for over 20 years. Adhering to the mission of “Simulate the World, Empower the Digital & Intelligent Future”, the Company continuously drives the digital transformation of China’s high-end manufacturing industry, and strives to become a pioneer in industrial simulation technology. It is the only CAE enterprise shortlisted in the 2024 Top 150 Chinese Software Enterprises (ranked 91st), released by Internet Weekly under the Chinese Academy of Sciences.

  • InnoModel Biotech

    http://www.imodels.tech/

    InnoModel Biotech (Beijing) Co., Ltd. was founded on September 28, 2020, focusing on providing preclinical pharmacology and efficacy CRO services. Its business scope covers in vivo and in vitro efficacy experiments related to tumors and tumor immunity, including non-GLP toxicology studies, PK/PD research, orthotopic models, drug distribution assessment, flow cytometry analysis and IND application trials.

  • Waytous

    http://www.waytous.com/

    WayTous (Beijing) Technology Co., Ltd. was founded in 2019. It is a smart mine technology enterprise incubated by the Institute of Automation, Chinese Academy of Sciences. It has evolved into an energy service provider and new energy manufacturer underpinned by artificial intelligence. The Company aims to become a global leader in unmanned and intelligent technologies. It leverages technological innovation to further advance China’s new energy security strategy, supports the high-quality development of domestic industry through intelligent construction, and empowers China’s mining industry to gain global discourse power in the digital era — making mines safer, greener, more efficient and smarter.

  • Echo Aiotech

    http://www.echobiotech.com/

    Echo Aiotech (Beijing) Biotechnology Co., Ltd. was founded in 2017. It is a biotechnology company dedicated to the technological development and clinical translation of exosomes. The Company has built three core platforms: the exosome multi-omics platform Exoomics®, the engineered exosome platform Echosome®, and the large-scale exosome production platform Echopharm®. It has established cooperative relationships with over 2,000 institutions at home and abroad, jointly published more than 300 research papers, covered over 100 sample types, and processed more than 80,000 samples in total.

  • Xnebula Info

    http://www.xnebula.com/

    Xnebula Information Technology (Wuxi) Co., Ltd. was founded in July 2018. It is a leading Chinese provider of integrated production automation solutions for semiconductor wafer fabs and semiconductor packaging & testing factories, primarily serving manufacturers in semiconductor wafer fabrication and packaging & testing sectors. The Company is currently one of the very few domestic high-tech enterprises capable of delivering integrated automation consulting and turnkey construction services for 8-inch and 12-inch wafer fabs. In the semiconductor packaging and testing field, it has broken the monopoly of international vendors across multiple technical directions and achieved world-class technological standards.

  • LittDD Biopharma

    http://www.zhongbocapital.com

    LittDD (Hangzhou) Pharmaceutical Technology Co., Ltd., formerly known as Shanghai Huiqi Biopharmaceutical Technology Co., Ltd., was founded in 2018. With in-depth insights into the biological mechanisms of drug targets, the Company identifies brand-new disease-driven signaling pathways and targets, and is committed to the research and development of globally innovative new drugs. It has independently built an AI-assisted multi-target compound design technology platform centered on the discovery of clinical therapeutic mechanisms of diseases. Combined with world-class capabilities in small molecule drug optimization and extensive successful experience in preclinical pharmaceutical research and early clinical development, the company has established an innovative drug R&D platform guided by precise disease mechanisms.

  • Spacetransportation

    https://www.spacetransportation.com.cn/

    Beijing Spacetransportation Technology Co., Ltd. was founded in August 2012. Its R&D headquarters is located in Beijing Economic and Technological Development Zone (Yizhuang), the power R&D center is situated in Xi’an, Shaanxi Province, and the rocket R&D and production base is built in Bengbu, Anhui Province. The Company’s R&D team is mainly composed of professionals from leading large aerospace industrial groups, with extensive experience in the overall design and development of engineering projects.

  • Innolake Biopharm

    http://www.innolakebio.com/

    Innolake Biopharma (Hangzhou) Co., Ltd. was established in 2020. It focuses on unmet medical needs in the fields of oncology and autoimmune diseases. The Company has built core technology platforms including novel-target small molecule drugs, innovative antibody therapeutics and novel ADC drugs. It owns globally original first-in-class small molecule pipelines and bispecific ADC pipelines. Multiple candidates are actively advancing in China-U.S. clinical trials and preclinical development, covering a batch of first-in-class or best-in-class projects with strong global competitive advantages.

  • CAS Space

    http://www.cas-space.com/

    CAS Space Technology Co., Ltd. is a leading commercial aerospace enterprise in China. Founded in December 2018, the Company is mainly engaged in the research and development, production and launch services of a series of medium and large commercial launch vehicles. It also explores new business forms of the space economy, including space manufacturing, space scientific experiments and space tourism. As a high-tech enterprise incubated by the Institute of Mechanics, Chinese Academy of Sciences, it inherits the rigorous research style of the Chinese Academy of Sciences. Always oriented toward serving national strategies and market demands, it gives full play to the advantages of the new nationwide system and the role of national strategic scientific and technological forces. The Company commits itself to building a high-efficiency, low-cost commercial aerospace system with Chinese characteristics, and aspires to become a world-class aerospace enterprise.

  • Hemacall Biotech

    https://www.xuejibio.com/

    Suzhou Hemacall Biotech Co., Ltd. was founded in June 2021. It is a stem cell biopharmaceutical company established by overseas returnee experts. The Company is committed to the directional regeneration of blood cells via stem cells for cell therapy of various diseases and the research and development of related drugs.Its founding team members hail from top domestic and international institutions, including Stanford University, Harvard University and Peking University.Leveraging its globally leading system for directed differentiation and induction of stem cells, Xueji Biotech takes ex vivo generated platelets as its flagship product. It aims to address the urgent shortage of platelets in the treatment of cancer, liver diseases, critical illnesses and hematological diseases, as well as to develop innovative drugs for various platelet-related disorders.

  • Moore Threads

    https://www.mthreads.com/

    Moore Threads was founded in 2020. Centered on full-featured GPUs, it is committed to providing global infrastructure and one-stop solutions for accelerated computing, delivering powerful AI computing support for the digital and intelligent transformation of all industries. The Company focuses on the R&D and design of full-featured GPU chips and related products, supporting diverse combined workloads including AI computing acceleration, 3D graphics rendering, ultra-high-definition video encoding and decoding, physical simulation and scientific computing. It has built an intelligent computing product line covering chips, graphics cards and clusters. Leveraging the diversified computing advantages of full-featured GPUs, Moore Threads aims to meet the growing demands for large model training and inference. With green and secure intelligent computing power, it vigorously promotes the implementation of applications such as large models, AIGC, scientific computing, digital twins, physical simulation and the metaverse, and drives high-quality development across all industries.

  • Zenshine Pharmaceuticals

    http://www.zenshine-pharma.com/

    Zenshine Pharmaceuticals (Nanjing) Group Co., Ltd. is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies to address unmet clinical needs in viral infectious diseases, oncology and inflammation.Dating back to 2018, the Company was founded by a seasoned leadership team with profound professional expertise and solid experience in biopharmaceutical R&D. Its flagship product Masiloxavir Tablets, a new-generation oral anti-influenza drug, has been approved for marketing by the National Medical Products Administration (NMPA).Zenshine Pharmaceutical is actively expanding the application scope of Masiloxavir. It is developing a dry suspension formulation for pediatric use, and advancing the indication expansion of the drug for post-exposure prophylaxis.

  • YOGO Robot

    https://www.yogorobot.com/

    Shanghai YOGO Robot Co., Ltd. was founded in 2016 with a registered capital of 12.8 million yuan. It is a globally leading enterprise dedicated to intelligent system R&D. To date, the Company has amassed over 2,000 patents in reserve, including more than 680 registered patents in the field of artificial intelligence, among which invention patents account for nearly 70%. It has also laid out a number of high-value international invention patents.

  • Null Hypothesis

    https://www.nullht.com/

    Shanghai Null Hypothesis Information Technology Co., Ltd. was founded in 2019, as a cutting-edge technology company dedicated to developing intelligent medical products.Its flagship KnowS product series deeply integrates data technology with professional medical expertise, enabling more professional and efficient knowledge transfer across the entire academic promotion workflow.The core team consists of multidisciplinary professionals graduated from prestigious universities including Tsinghua University, Fudan University, Shanghai Jiao Tong University and East China University of Science and Technology (including their respective medical and pharmaceutical schools), with strong expertise in integrating medical professionalism and data analytics technology.

Keep a close eye on the endless frontier of technological progress. Adopt first principles to identify great tech investment targets. We shun fleeting trends and focus in-depth on our core domains.

Investment Philosophy

Rooted in technology, committed to value. We conduct research from macro outlook down to individual enterprises. We embrace tech advancement and uphold value investment. We fuel industrial growth with professionalism, accelerate the conversion of leading-edge technologies into people-benefiting productivity, and strive to boost China’s high-tech development for the next two decades.

Insights

View more perspectives